Inhibikase Therapeutics, Inc. (IKT)
| Previous close | 1.8600 |
| Open | 1.6700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6700 - 1.7313 |
| 52-week range | 0.7900 - 4.3500 |
| Volume | |
| Avg. volume | 103,901 |
| Market cap | 11.213M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.5700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.50 |
GlobeNewswireInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 2
- GlobeNewswire
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company will meet wi
Simply Wall St.Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...
